03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
22:01 , Nov 16, 2017 |  BC Extra  |  Financial News

Protein misfolding play Orphazyme prices IPO

Protein misfolding company Orphazyme A/S (CSE:ORPHA TEMP) was unchanged on Thursday after it debuted on NASDAQ Copenhagen, raising DKK 600 million ($94.1 million) in an IPO through the sale of 7.5 million shares at DKK...
19:22 , Jul 28, 2017 |  BioCentury  |  Regulation

Ganging up in rare disease

A joint proposal from EMA and FDA that encourages companies to join multidrug platform trials for pediatric Gaucher’s disease came too late to serve its original purpose. But the proposal could provide a template for...
21:46 , Mar 10, 2017 |  BC Extra  |  Financial News

Protein misfolding company Orphazyme adds €14M to series B

Orphazyme ApS (Copenhagen, Denmark) added €14 million ($14.9 million) in the second and final close of its series B round, bringing the round's total to €34 million. New investors LSP and the ALS Investment Fund...
20:56 , Mar 10, 2017 |  BC Week In Review  |  Financial News

Orphazyme completes venture financing

On March 8, metabolic and neurological disease company Orphazyme ApS (Copenhagen, Denmark) raised €14 million ($14.9 million) in an extension of a series B round. New investors LSP and the ALS Investment Fund and existing...
22:04 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

Arimoclomol: Ph II data

A double-blind, placebo-controlled, U.S. and Canadian Phase II trial in 36 patients with rapidly progressive familial ALS due to mutations in the superoxide dismutase 1 (SOD1) gene showed that thrice-daily 200 mg oral arimoclomol for...
07:00 , Aug 22, 2016 |  BioCentury  |  Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

Arimoclomol: Phase III started

Orphazyme began the double-blind, placebo-controlled, international Phase III NPC-002 trial to evaluate oral arimoclomol thrice daily plus standard of care (SOC) for 12 months in about 46 patients. Orphazyme ApS, Copenhagen, Denmark   Product: Arimoclomol (OR-01)...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Heat shock protein 70 (Hsp70)

Neurology INDICATION: Cognitive dysfunction Mouse studies suggest Hsp70 could help treat age-related cognitive dysfunction. In aged mice, intranasal administration of human Hsp70 for up to five months increased neuronal density in the hippocampus, spatial memory function and...